---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-069067"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:18:21.912456+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio gets FDA Fast Track for ADI-001 in lupus nephritis; Phase 1 starts this month

## Summary
- FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III or IV lupus nephritis.
- Company plans to initiate Phase 1 clinical study in lupus nephritis in June 2024.
- ADI-001 previously showed CD19+ B-cell depletion in non-Hodgkin's lymphoma, similar to CAR T data in autoimmune diseases.
- CEO Chen Schor cites urgent unmet need and plans to expand autoimmune program beyond lupus nephritis.

## SEC filing metadata
- accession: 0000950170-24-069067
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/0000950170-24-069067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/acet-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-069067
- JSON: https://secwatch.observer/filing/0000950170-24-069067.json
- Plain text: https://secwatch.observer/filing/0000950170-24-069067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.